Identification

Name
Suprofen
Accession Number
DB00870  (APRD00230)
Type
Small Molecule
Groups
Approved, Withdrawn
Description

An ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.

Structure
Thumb
Synonyms
  • (+-)-2-(P-(2-Thenoyl)phenyl)propionic acid
  • 2-(4-(2-Thenoyl)phenyl)propionsaeure
  • 2-[4-(Thiophene-2-carbonyl)-phenyl]-propionic acid
  • 4-(2-Thenoyl)hydratropsaeure
  • alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid
  • P-2-Thenoylhydratropic acid
  • Suprofen
  • Suprofène
  • Suprofene
  • Suprofeno
  • Suprofenum
  • SUTOPROFEN
External IDs
R 25061 / TN 762
International/Other Brands
Profenal (Janssen Pharmaceuticals) / Srendam (Pola Pharma) / Sulprotin (Taiyo Pharmaceutical) / Topalgic (Alfresa Pharma)
Categories
UNII
988GU2F9PE
CAS number
40828-46-4
Weight
Average: 260.308
Monoisotopic: 260.05071494
Chemical Formula
C14H12O3S
InChI Key
MDKGKXOCJGEUJW-UHFFFAOYSA-N
InChI
InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)
IUPAC Name
2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid
SMILES
CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1

Pharmacology

Indication

Used as eye drops to inhibit the miosis (pupil constriction) that may occur during ocular surgery.

Structured Indications
Not Available
Pharmacodynamics

Suprofen is a non-steroidal anti-inflammatory analgesic and antipyretic. Ophthalmic anti-inflammatory medicines are used in the eye to lessen problems that can occur during or after some kinds of eye surgery. Sometimes, the pupil of the eye gets smaller during an operation (pupil constriction), making it more difficult for the surgeon to reach some areas of the eye. Suprofen is used to help prevent this.

Mechanism of action

Suprofen binds to the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes, preventing the synthesis of prostaglandins and reducing the inflammatory response. Cyclooxygenase catalyses the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A2). Prostaglandins act (among other things) as messenger molecules in the process of inflammation. The overall result is a reduction in pain and inflammation in the eyes and the prevention of pupil constriction during surgery. Normally trauma to the anterior segment of the eye (especially the iris) increases endogenous prostaglandin synthesis which leads to constriction of the iris sphincter.

TargetActionsOrganism
AProstaglandin G/H synthase 1
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

20%

Metabolism

Primarily hepatic (mainly via cytochrome P450 isozyme 2C9).

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose include bleeding in the eye or redness or swelling of the eye or the eyelid, blurred vision or other change in vision, fever or chills, itching or tearing, nausea or vomiting, pain, sensitivity to light, shortness of breath, sticky or matted eyelashes, swelling of face, throbbing pain, tightness in chest, troubled breathing, and wheezing.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Suprofen Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Suprofen is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Suprofen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Suprofen is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Suprofen is combined with 5-androstenedione.Experimental, Illicit
AbciximabSuprofen may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Suprofen can be decreased when combined with Abiraterone.Approved
AcebutololSuprofen may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Suprofen is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Suprofen is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolSuprofen may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinSuprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Suprofen.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Suprofen is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Suprofen is combined with Aldosterone.Experimental, Investigational
AldoxorubicinSuprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Alendronic acid.Approved
AliskirenSuprofen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Alminoprofen.Experimental
AlprenololSuprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Suprofen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Suprofen is combined with Amcinonide.Approved
AmikacinSuprofen may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideSuprofen may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Suprofen can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinSuprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodSuprofen may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Suprofen is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Suprofen is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Suprofen is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Suprofen is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Suprofen is combined with Anisodamine.Investigational
AnnamycinSuprofen may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Suprofen is combined with Antipyrine.Approved, Investigational
Antithrombin III humanSuprofen may increase the anticoagulant activities of Antithrombin III human.Approved
ApalutamideThe serum concentration of Suprofen can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanSuprofen may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Suprofen is combined with Apocynin.Investigational
ApramycinSuprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Suprofen is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Suprofen can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinSuprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinSuprofen may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanSuprofen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololSuprofen may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Suprofen is combined with Atamestane.Investigational
AtenololSuprofen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Suprofen is combined with Azelastine.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Suprofen is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Suprofen.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Suprofen.Investigational
BalsalazideSuprofen may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminSuprofen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Suprofen is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololSuprofen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinSuprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Suprofen is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Suprofen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Suprofen is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Suprofen is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Suprofen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Betamethasone.Approved, Vet Approved
BetaxololSuprofen may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Suprofen.Approved, Investigational
BevantololSuprofen may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Suprofen is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Suprofen.Approved, Investigational
BisoprololSuprofen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinSuprofen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololSuprofen may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Suprofen.Approved
BucillamineThe risk or severity of adverse effects can be increased when Suprofen is combined with Bucillamine.Investigational
BucindololSuprofen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Suprofen is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Suprofen is combined with Bufexamac.Approved, Experimental
BufuralolSuprofen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Suprofen.Approved
BupranololSuprofen may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Suprofen.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Suprofen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Suprofen is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Suprofen can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Captopril.Approved
CarbamazepineThe metabolism of Suprofen can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Suprofen is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Suprofen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Suprofen.Approved, Vet Approved, Withdrawn
CarteololSuprofen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolSuprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Suprofen is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Celecoxib.Approved, Investigational
CeliprololSuprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Suprofen can be increased when it is combined with Ceritinib.Approved
CertoparinSuprofen may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Suprofen.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Suprofen.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Suprofen.Approved
CholecalciferolThe metabolism of Suprofen can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Suprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Suprofen is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Suprofen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Cilazapril.Approved
CinoxacinSuprofen may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidSuprofen may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Suprofen is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Suprofen is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Suprofen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Suprofen is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Suprofen.Vet Approved
CloranololSuprofen may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Suprofen can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Suprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Suprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Suprofen is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Suprofen is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Suprofen is combined with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Suprofen can be decreased when combined with Crisaborole.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Suprofen is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Suprofen.Experimental
CyclosporineSuprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateSuprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Suprofen can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalteparinSuprofen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSuprofen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanSuprofen may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinSuprofen may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Suprofen is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Suprofen is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Delapril.Experimental
DelavirdineThe metabolism of Suprofen can be decreased when combined with Delavirdine.Approved
DesirudinSuprofen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Suprofen is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Suprofen is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Suprofen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Suprofen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Suprofen is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Suprofen.Approved, Investigational
DextranSuprofen may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Suprofen may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Suprofen may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Suprofen may increase the anticoagulant activities of Dextran 75.Approved
DibekacinSuprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Suprofen is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Suprofen.Approved, Vet Approved
DicoumarolSuprofen may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Suprofen is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Suprofen.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Suprofen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Suprofen.Approved
DihydrostreptomycinSuprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Suprofen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Suprofen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Suprofen.Approved
DosulepinThe metabolism of Suprofen can be decreased when combined with Dosulepin.Approved
DoxorubicinSuprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneSuprofen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Suprofen is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Suprofen is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Suprofen is combined with E-6201.Investigational
Edetic AcidSuprofen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSuprofen may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Suprofen can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Suprofen is combined with Enalaprilat.Approved
EnoxacinSuprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinSuprofen may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Suprofen.Experimental
EpanololSuprofen may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Suprofen is combined with Epirizole.Approved
EpirubicinSuprofen may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Suprofen.Experimental
EplerenoneSuprofen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Suprofen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Suprofen.Approved
EquileninThe risk or severity of adverse effects can be increased when Suprofen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Suprofen is combined with Equilin.Approved
EsmololSuprofen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Suprofen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Suprofen is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Suprofen.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Suprofen.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Suprofen is combined with Ethenzamide.Experimental
Ethyl biscoumacetateSuprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Suprofen is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Suprofen is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Suprofen can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Suprofen is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Suprofen is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Suprofen is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Suprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Suprofen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Suprofen is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Feprazone.Experimental
Ferulic acidSuprofen may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Suprofen.Approved, Investigational
FleroxacinSuprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Suprofen.Approved, Withdrawn
FloxuridineThe metabolism of Suprofen can be decreased when combined with Floxuridine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Suprofen can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Fludrocortisone.Approved, Investigational
FluindioneSuprofen may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineSuprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Suprofen is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Suprofen is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluorometholone.Approved, Investigational
FluorouracilThe metabolism of Suprofen can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Suprofen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Suprofen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Suprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Suprofen can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Suprofen can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Suprofen.Approved, Nutraceutical, Vet Approved
FondaparinuxSuprofen may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumSuprofen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Suprofen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Suprofen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Suprofen can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinSuprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Suprofen.Approved, Vet Approved
GabexateSuprofen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinSuprofen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSuprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Suprofen.Approved, Withdrawn
GemfibrozilThe metabolism of Suprofen can be decreased when combined with Gemfibrozil.Approved
GemifloxacinSuprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinSuprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinSuprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ASuprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Suprofen may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinSuprofen may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Suprofen is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Suprofen is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Suprofen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Suprofen is combined with HE3286.Investigational
HeparinSuprofen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Suprofen is combined with Higenamine.Investigational
HydralazineSuprofen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Suprofen.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Suprofen.Approved, Investigational
Hygromycin BSuprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Suprofen is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Suprofen is combined with Icatibant.Approved, Investigational
IdarubicinSuprofen may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxSuprofen may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Suprofen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Suprofen is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Suprofen.Approved
IndenololSuprofen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Suprofen can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Suprofen is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Suprofen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Indoprofen.Withdrawn
IrbesartanThe metabolism of Suprofen can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinSuprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Suprofen is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Suprofen is combined with Istaroxime.Investigational
KanamycinSuprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Suprofen can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Suprofen.Approved
LabetalolSuprofen may decrease the antihypertensive activities of Labetalol.Approved
LandiololSuprofen may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Suprofen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Suprofen.Approved, Investigational
LeflunomideThe metabolism of Suprofen can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinSuprofen may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanSuprofen may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololSuprofen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSuprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Suprofen.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Suprofen is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Suprofen.Approved
LobeglitazoneThe metabolism of Suprofen can be decreased when combined with Lobeglitazone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Suprofen is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Suprofen is combined with Lornoxicam.Approved, Investigational
LosartanThe metabolism of Suprofen can be decreased when combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Suprofen is combined with Loteprednol.Approved
LovastatinThe metabolism of Suprofen can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Suprofen.Approved, Investigational
LumacaftorThe serum concentration of Suprofen can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Suprofen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Suprofen is combined with Magnesium salicylate.Approved
ManidipineThe metabolism of Suprofen can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Suprofen.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Suprofen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Suprofen.Approved
MelagatranSuprofen may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Suprofen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Suprofen.Approved, Vet Approved
MepindololSuprofen may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineSuprofen may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Suprofen is combined with Metamizole.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Suprofen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Suprofen.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Methylprednisolone.Approved, Vet Approved
MetipranololSuprofen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Suprofen.Approved
MetoprololSuprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideSuprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinSuprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Suprofen can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Suprofen.Approved, Experimental
MifepristoneThe serum concentration of Suprofen can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Suprofen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Suprofen is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Suprofen.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Suprofen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Nabumetone.Approved
NadololSuprofen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinSuprofen may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatSuprofen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Suprofen.Approved
Nalidixic AcidSuprofen may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Suprofen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Suprofen is combined with NCX 1022.Investigational
NeamineSuprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololSuprofen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinSuprofen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinSuprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Suprofen.Approved, Investigational
NetilmicinSuprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe metabolism of Suprofen can be decreased when combined with Nicardipine.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Suprofen is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Suprofen is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Suprofen is combined with Nitroaspirin.Investigational
NorfloxacinSuprofen may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Suprofen is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Suprofen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Suprofen.Approved
OlsalazineSuprofen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Suprofen is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Suprofen is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Suprofen can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Suprofen is combined with Orgotein.Vet Approved
OtamixabanSuprofen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Suprofen is combined with Oxaprozin.Approved
Oxolinic acidSuprofen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololSuprofen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Oxyphenbutazone.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Parecoxib.Approved
ParomomycinSuprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Suprofen is combined with Parthenolide.Approved, Investigational
PazufloxacinSuprofen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSuprofen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololSuprofen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateSuprofen may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateSuprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Perindopril.Approved
PhenindioneSuprofen may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Suprofen can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonSuprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Suprofen.Approved, Vet Approved
PhenytoinThe metabolism of Suprofen can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Suprofen.Approved, Investigational
PindololSuprofen may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidSuprofen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinSuprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Suprofen.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Pirfenidone.Approved, Investigational
Piromidic acidSuprofen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Suprofen.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Suprofen is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorSuprofen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinSuprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinSuprofen may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Suprofen.Approved
PractololSuprofen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Suprofen.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Suprofen is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Suprofen is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Suprofen is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe metabolism of Suprofen can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Suprofen can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Suprofen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Suprofen is combined with Propacetamol.Approved, Investigational
PropranololSuprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Suprofen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Suprofen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Suprofen.Vet Approved
Protein CSuprofen may increase the anticoagulant activities of Protein C.Approved
Protein S humanSuprofen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSuprofen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinSuprofen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Suprofen is combined with PTC299.Investigational
PuromycinSuprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Suprofen can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Suprofen.Approved
QuinineThe metabolism of Suprofen can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Suprofen is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Suprofen is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinSuprofen may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinSuprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifampicinThe metabolism of Suprofen can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Suprofen can be increased when combined with Rifapentine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Risedronate.Approved, Investigational
RivaroxabanSuprofen may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinSuprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe metabolism of Suprofen can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinSuprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinSuprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Suprofen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Suprofen is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Suprofen is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Suprofen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Suprofen.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Suprofen.Approved, Investigational
SecobarbitalThe metabolism of Suprofen can be increased when combined with Secobarbital.Approved, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Suprofen is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Suprofen is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Suprofen is combined with Serrapeptase.Investigational
SildenafilThe metabolism of Suprofen can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinSuprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinSuprofen may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Suprofen.Approved
SorafenibThe metabolism of Suprofen can be decreased when combined with Sorafenib.Approved, Investigational
SotalolSuprofen may decrease the antihypertensive activities of Sotalol.Approved
SP1049CSuprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinSuprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinSuprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Spirapril.Approved
SpironolactoneSuprofen may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Suprofen is combined with SRT501.Investigational
StreptomycinSuprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinSuprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SulfadiazineThe metabolism of Suprofen can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Suprofen can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Suprofen.Approved
SulfisoxazoleThe metabolism of Suprofen can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Suprofen.Approved, Investigational
SulodexideSuprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Suprofen.Investigational
SuxibuzoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Suxibuzone.Experimental
TacrolimusSuprofen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Suprofen.Approved
TalinololSuprofen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Suprofen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Suprofen is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Suprofen.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Suprofen.Approved, Investigational
TemafloxacinSuprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Suprofen is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Suprofen is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Suprofen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Suprofen is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Suprofen is combined with Teriflunomide.Approved
TertatololSuprofen may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Suprofen can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Suprofen can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololSuprofen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Suprofen is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Suprofen is combined with Tixocortol.Approved, Withdrawn
TobramycinSuprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Suprofen can be decreased when combined with Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Suprofen is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Suprofen.Approved
TopiroxostatThe metabolism of Suprofen can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Suprofen.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Suprofen is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Suprofen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Suprofen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneSuprofen may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Suprofen is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Suprofen.Approved, Vet Approved
TrimethoprimThe metabolism of Suprofen can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Suprofen is combined with Triptolide.Investigational
TrovafloxacinSuprofen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinSuprofen may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Suprofen is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Suprofen.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Suprofen can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinSuprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Suprofen can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Suprofen.Approved
VoriconazoleThe metabolism of Suprofen can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinSuprofen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSuprofen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Suprofen can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Suprofen.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Suprofen is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Suprofen is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinSuprofen may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinSuprofen may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015008
KEGG Drug
D00452
KEGG Compound
C07320
PubChem Compound
5359
PubChem Substance
46508210
ChemSpider
5166
BindingDB
50090676
ChEBI
9362
ChEMBL
CHEMBL956
Therapeutic Targets Database
DAP000730
PharmGKB
PA451569
Drugs.com
Drugs.com Drug Page
Wikipedia
Suprofen
ATC Codes
M01AE07 — Suprofen
MSDS
Download (50.8 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Alcon laboratories inc
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)124.3 °CPhysProp
water solubilitylimited solubilityNot Available
logP2.2Not Available
pKa3.91MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0422 mg/mLALOGPS
logP3.16ALOGPS
logP3.53ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)4.01ChemAxon
pKa (Strongest Basic)-7.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity69.41 m3·mol-1ChemAxon
Polarizability26.84 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9927
Blood Brain Barrier+0.9289
Caco-2 permeable+0.6039
P-glycoprotein substrateNon-substrate0.7298
P-glycoprotein inhibitor INon-inhibitor0.9534
P-glycoprotein inhibitor IINon-inhibitor0.9664
Renal organic cation transporterNon-inhibitor0.8998
CYP450 2C9 substrateNon-substrate0.6293
CYP450 2D6 substrateNon-substrate0.9226
CYP450 3A4 substrateNon-substrate0.8098
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.8607
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.8958
CYP450 3A4 inhibitorNon-inhibitor0.9526
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.9398
CarcinogenicityNon-carcinogens0.7568
BiodegradationReady biodegradable0.7714
Rat acute toxicity3.1892 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9869
hERG inhibition (predictor II)Non-inhibitor0.9716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-2790000000-0cf8f983c8b216c951b3

Taxonomy

Description
This compound belongs to the class of organic compounds known as aryl-phenylketones. These are aromatic compounds containing a ketone substituted by one aryl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Aryl-phenylketones
Alternative Parents
Phenylpropanoic acids / Monocyclic monoterpenoids / Aromatic monoterpenoids / Thiophene carboxylic acids and derivatives / Benzoyl derivatives / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
Substituents
Aryl-phenylketone / 2-phenylpropanoic-acid / P-cymene / Aromatic monoterpenoid / Monocyclic monoterpenoid / Monoterpenoid / Benzoyl / Thiophene carboxylic acid or derivatives / Benzenoid / Monocyclic benzene moiety
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid, thiophenes, aromatic ketone (CHEBI:9362)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Loll PJ, Picot D, Ekabo O, Garavito RM: Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry. 1996 Jun 11;35(23):7330-40. [PubMed:8652509]
  2. Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, Urban L, Whitebread S, Jenkins JL: Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem. 2007 Jun;2(6):861-73. [PubMed:17477341]
  3. Llorens O, Perez JJ, Palomer A, Mauleon D: Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71. [PubMed:11885959]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Llorens O, Perez JJ, Palomer A, Mauleon D: Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71. [PubMed:11885959]

Enzymes

Details
1. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 02:04